How FDA Reviews Cell & Gene Therapies: A Deep-Dive Regulatory Guide

Imagine a world where devastating genetic diseases or aggressive cancers aren’t just managed—but potentially cured with a single treatment. That’s the promise of cell and gene therapies(CGTs), the most exciting frontier in modern medicine today.

These innovative treatments work by harnessing the body’s own cells or directly modifying genes to fight disease at its root. Key examples include:

CAR-T cell therapies : Engineered immune cells that target and destroy cancer cells, revolutionizing treatment for certain blood cancers.

AAV-based gene therapies : Viral vectors that deliver healthy genes to replace faulty ones in conditions like inherited retinal diseases or haemophilia.

CRISPR gene editing : Precision tools to correct genetic mutations, as seen in groundbreaking approvals for sickle cell disease.

In 2025, the impact is clearer than ever, with CGTs delivering life-changing, often durable results for patients with rare genetic disorders and haematological conditions.

Why CGTs Are Unique—and Challenging

Unlike traditional drugs, CGTs involve living cells, viral delivery systems, or permanent changes to DNA. This introduces complexities like:

• Batch-to-batch variability in manufacturing.
• Potential long-term risks, such as immune reactions or unintended genetic effects.

These factors demand specialized production, rigorous quality controls, and careful patient monitoring.

Enhancing CMC/Module 3 Documentation with Gen AI Whitepaper

This whitepaper serves as a guide for regulatory, CMC, and digital innovation teams looking to integrate AI in their authoring workflows. Whether you’re seeking faster submissions, improved consistency, or scalability across regions, the insights in this paper are designed to help.

Download the Whitepaper

Navigating Rigorous FDA Oversight

To ensure safety and efficacy, CGTs face one of the most structured review processes at the U.S. Food and Drug Administration (FDA). Reviews are handled by the Center for Biologics Evaluation and Research (CBER)’s Office of Therapeutic Products (OTP), guided by dedicated policies on manufacturing, potency testing, clinical design, and long-term follow-up.

As of late 2025, the pipeline is thriving :

• Over 3,200 active clinical trials worldwide.
• Several new approvals this year, including therapies for rare conditions like Wiskott-Aldrich syndrome and recessive dystrophic epidermolysis bullosa.
• The FDA on track toward its projection of 10–20 annual approvals and this leads to effective presentation of the data for easier and efficient review process.

1. Regulatory Framework for Cell & Gene Therapies

CGTs are regulated under the Public Health Service Act (PHS Act) and relevant sections of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The oversight sits with:

• CBER – Center for Biologics Evaluation and Research
• OTAT – Office of Tissues and Advanced Therapies (primary review office)

Products are reviewed as:

• 351 products, requiring a BLAs (Biologics License Applications)
• Combination products (e.g., cells + biomaterials, gene therapy + device) when applicable

The FDA’s burden is to ensure:

• Scientific validity
• Manufacturing consistency
• Long-term safety
• Clinical benefit that outweighs risks

2. Pre-IND Engagement: Why FDA Encourages Early Dialogue

FDA guidance strongly stresses early interaction, often through :

INTERACT Meeting

For novel or first-in-human technologies (CRISPR, base editing, ex vivo gene editing), providing FDA the chance to comment on:

• Vector selection
• Cell source (autologous vs allogeneic)
• Proposed release testing
• Need for animal models
• High-risk toxicology triggers
• Safety endpoints

Pre-IND Meeting

Used to discuss submission strategy including :

• Adequacy of CMC package
• Sufficiency of biodistribution and tumorigenicity study designs
• Proposed potency assay development plan
• Immunogenicity monitoring plan
• Dose selection rationale

Why it matters :

CGTs frequently lack conventional pharmacology and toxicology pathways. Early feedback prevents missteps that could derail IND acceptance.

3. IND Application Review: Scientific & Regulatory Depth

To initiate human studies, the FDA evaluates the IND, focusing on three major pillars :

1. Nonclinical Requirements (Biodistribution, Toxicology & Tumorigenicity)
   1. Biodistribution Studies

      Critical for viral vectors (AAV, lentivirus, adenovirus) and genome editing tools. FDA assesses:

      • Organ tropism
      • Persistence and clearance kinetics
      • Transgene expression duration
      • Potential germline transmission
      • Shedding (in biological fluids)

      Models may be :

      • Animal models resembling human disease (e.g., DMD mouse models)
      • Humanized mouse models for immunogenicity
      • Large animal models for CNS or ocular gene therapies
   2. Toxicology Studies

      Often require GLP-compliant studies that evaluate :

      • Dose–response profiles
      • Target organ toxicity
      • Immune activation
      • Off-target genome editing effects

      For CRISPR-based therapies, the FDA expects comprehensive off-target mapping, integrating :

      • In silico predictions
      • In vitro nuclease activity data
      • Deep sequencing analysis
   3. Tumorigenicity / Oncogenicity Risk

      FDA expects :

      • Insertional mutagenesis assessment
      • Stem cell pluripotency persistence
      • Genomic stability testing

   These nonclinical packages must justify the rationale for first-in-human dosing.

2. CMC (Chemistry, Manufacturing and Controls) – The Most Critical Section

   FDA guidance places enormous emphasis on CMC because manufacturing changes dramatically influence the safety and efficacy of CGTs.

   1. Starting Materials & Raw Materials

      FDA expects detailed information on :

      • Viral vector plasmids (identity, purity, sequence verification)
      • Cell banks (Master Cell Bank & Working Cell Bank)
      • Donor eligibility determination (for autologous products)
      • Animal-origin components (serum, cytokines, media)
      • Reagents used in gene editing (Cas9 protein, guide RNA)
   2. Manufacturing Process

      Sponsors must provide :

      • Detailed manufacturing flow charts
      • Critical process parameters (CPPs)
      • Critical quality attributes (CQAs)
      • In-process controls
      • Process validation strategy
      • Viral clearance and testing standards
      • Transduction efficiency data
      • Data on culture conditions and expansion methods

      Highly variable materials (e.g., patient-derived T cells) require stringent controls to ensure consistent product performance.

   3. Release Specifications

      Release Specifications

      • Identity (cell-surface markers, genomic markers)
      • Purity (host cell DNA, replication competent virus, impurities)
      • Potency (functional activity assays)
      • Viability (flow cytometry)
      • Safety (sterility, mycoplasma, endotoxin)
      • Vector copy number (VCN)
   4. Potency Assay Strategy

      Per FDA guidance, potency assays must measure the biological activity related to the therapeutic effect. Examples :

      • Cytotoxicity assays for CAR-T cells
      • Transgene expression assays (qPCR, ELISA)
      • Functional gene correction assays

      Potency assays often evolve during development; FDA requires justification for interim assays.

3. Clinical Protocol ReviewThe FDA examines :

   1. Dose Selection & Escalation

      Because CGTs can trigger intense immune responses or durable effects, dose steps must be conservative. FDA evaluates :

      • Safety margins based on biodistribution
      • Vector dose calculations (viral genomes/kg)
      • Maximum feasible doses
      • Risk mitigation strategies
   2. Patient Monitoring Plans

      Must be extremely detailed for CGTs, including:

      • Monitoring for cytokine release syndrome (CRS)
      • Neurotoxicity (ICANS)
      • Vector shedding
      • Liver toxicity (especially with AAV vectors)
      • Insertional oncogenicity
   3. Stopping Rules & Safety Overrides

      FDA expects predefined criteria including :

      • Grade 3/4 immune reactions
      • Persistent viremia
      • Organ-specific toxicity
      • Unexpected gene editing signatures
   4. Informed Consent Requirements

      Must clearly articulate :

      • Lifelong monitoring risks
      • Unknown long-term consequences
      • Potential for irreversible genetic modification

4. FDA’s Clinical Review: Safety, Efficacy & Benefit–Risk Balance

1. Safety Review

   FDA evaluates :

   • Immediate infusion reactions
   • Cytokine release syndrome (CRS) severity (CAR-T therapies)
   • Hepatotoxicity (AAV vectors)
   • On-target/off-target editing
   • Autoimmune activation
   • Autoimmune activation
2. Efficacy Review

   Given rare disease constraints, FDA allows flexibility :

   • Single-arm trials
   • Historical controls
   • Biomarkers or surrogate endpoints (e.g., dystrophin expression for DMD)
   • Early signals with long-term follow-up
3. Benefit–Risk Evaluation

   FDA’s decision focuses on whether the therapy :

   • Offers substantial potential benefit
   • Addresses unmet medical needs
   • Has risks that are manageable and monitored
   • Shows consistent CMC and potency outcomes

5. Long-Term Follow-Up (LTFU) Requirements: A Key FDA Demand

Gene therapies often require up to 15 years of monitoring, depending on :

• Vector type (AAV, LV, RV, HSV)
• Integration potential
• Persistence and biodistribution
• Risk of germline modification

Sponsors must submit LTFU plans that include :

• Clinical exams
• Laboratory monitoring
• Vector persistence analysis
• Cancer surveillance
• Genomic integration monitoring

6. Post-Marketing Requirements (PMRs) & Pharmacovigilance

Once approved, CGTs often include :

• Post-marketing clinical trials
• Updated potency assay validation
• Manufacturing comparability after scale-up
• REMS (Risk Evaluation and Mitigation Strategies) for high-risk products
• Mandatory adverse event reporting

7. FDA Expedited Programs for Cell & Gene Therapies

FDA offers multiple accelerated pathways :

1. RMAT (Regenerative Medicine Advanced Therapy)
   • Exclusive to regenerative therapies
   • Provides intensive FDA guidance
2. Breakthrough Therapy Designation
   • For products showing substantial improvement over available therapy.
3. Fast Track & Priority Review
   • Speed up development and review timelines.
4. Accelerated Approval
   • Allows use of surrogate endpoints with post-approval commitments.
   • Many CGTs qualify because they target serious, rare, or life-threatening diseases.

Conclusion

FDA’s review of cell and gene therapies is exceptionally comprehensive, reflecting the delicate balance between innovation and patient safety. Understanding the FDA’s expectations across CMC, nonclinical, clinical, long-term safety, and post-marketing phases is essential for any sponsor seeking approval in this rapidly evolving field.

Companies that engage early with the FDA, invest in robust manufacturing controls, and anticipate long-term safety requirements position themselves for streamlined development and regulatory success.

Learn how expert CMC writers can strengthen documentation, support global submissions, and help teams progress faster through development. Contact us at info@celegence.com.